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Abstract. Oxidative stress plays an essential and early role in the pathophysiology of Alzheimer’s disease (AD). Alterations
in the redox state in AD and in mild cognitive impairment (MCI) patients appear in the brain and at peripheral level. Given
that it is easier to study the latter, most of the research has been focused on plasma. However, the analysis of redox parameters
in whole blood cells (including erythrocytes and leukocytes) has not really been investigated. Moreover, the association
of these parameters with Mini-Mental State Examination (MMSE) clinical scores, has scarcely been studied. Therefore,
the aim of the present work was to analyze several redox markers in whole blood cells from male and female MCI and AD
patients. Antioxidant (superoxide dismutase, catalase (CAT), glutathione peroxidase (GPx), and reductase (GR) activities, and
reduced glutathione (GSH) concentration) together with oxidant parameters (oxidized glutathione (GSSG) and thiobarbituric
acid-reactive substances (TBARS)) were investigated using MCI and AD (10 women and 10 men in each group) and their
age-matched control groups (15 women and 15 men). The results show an altered redox state in whole blood cells from AD
patients (higher CAT, GSSG/GSH, TBARS and lower GPx, GR, GSH). Some of these redox parameters are already affected
in MCI patients (higher TBARS and lower GPx and GR activities) in both sexes and, consequently, they could be used as
markers of prodromal AD. Since GR, GSH, GSSG, and GSSG/GSH were found to be associated with MMSE scores, they
seem to be useful clinically to monitor cognitive decline in AD progression.
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INTRODUCTION25
Due to the increasing average lifespan, the clinical26
relevance of Alzheimer’s disease (AD) is exponen-27
tially rising and is expected to become a pandemic28
and public health burden. Thus, it is estimated that
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the prevalence of AD may reach > 115 million world- 29
wide by 2050 [1]. The sporadic form, which is the 30
most common cause of AD (>95% of cases) has a late 31
age of onset and it is strongly associated with aging 32
[2, 3]. One of the main obstacles of a potential AD 33
cure is that it is only diagnosed in later stages of the 34
disease, in which there is already irreversible brain 35
damage. However, numerous longitudinal follow-up 36
studies clearly demonstrated that AD dementia is pre- 37
ceded by a long asymptomatic (preclinical) phase 38
followed by a transitional stage with mild cogni- 39
tive impairment (MCI) [4–6]. Thus, this intermediate 40
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stage offers an important opportunity for possible41
diagnosis, prevention and therapeutic interventions.42
It is now recognized that only a combination of43
biomarkers will define a patient-specific signature to44
diagnose AD in the future [7]. Although the accu-45
mulation of amyloid and tau proteins is considered46
the core pathologic hallmark for AD, other factors47
such as oxidative stress and inflammation, contribute48
enormously to its complex pathophysiology. In this49
context, it is now well established that oxidative stress50
plays a pivotal role in the pathophysiology and the51
progression of AD. Nunomura et al. [8] showed that52
oxidative stress in brain precedes the development53
of the neuropathological hallmarks of AD such as54
the extracellular senile plaques formed by amyloid-55
(A) peptide and the neurofibrillary tangles consist-56
ing of abnormally phosphorylated tau protein. In fact,57
some evidence has suggested that the A deposition58
in certain neurons may be considered an effort to pro-59
tect these cells against damage due to oxidative stress60
[9–11]. A deposition has also been associated with61
neuronal lipid, protein, and DNA oxidation in animal62
models of AD [12–14], whereas in humans, oxida-63
tive damage to biomolecules has also been reported64
in the brain of both AD and MCI patients [15, 16]. In65
addition, several studies have shown that the oxida-66
tive alterations in AD and in MCI patients are not only67
limited to the brain but they have also been detected in68
the blood compartment [17–19]. Nevertheless, both69
establishing the right pattern of redox markers to ana-70
lyze as well as choosing the most appropriate sample71
type remain a challenge in AD. Most of the studies72
have been focused on the search for redox markers in73
plasma or serum [19, 20]. However, the redox status74
of erythrocytes is essential for adequate oxygen deliv-75
ery to the whole body. In fact, an impaired oxygen76
delivery to the brain causing neuronal AD dysfunc-77
tion, has been considered an important factor in AD78
[21]. Moreover, the redox state of immune cells has79
been shown to be crucial for their adequate defensive80
functioning [17]. Actually, a higher oxidative stress81
has been linked to a premature immunosenescence in82
leukocytes from AD patients and to an uncontrolled83
higher release of pro-inflammatory mediators which84
also contribute to AD pathology [17].85
Therefore, in order to identify non-invasive redox86
markers that can be used for an early diagnosis87
of AD, we decided to investigate several param-88
eters of oxidative stress in whole blood cells89
(containing erythrocytes and leukocytes). Thus,90
antioxidant enzyme activities and compounds (super-91
oxide dismutase (SOD), catalase (CAT), glutathione92
peroxidase (GPx), glutathione reductase (GR), and 93
reduced glutathione (GSH) concentrations) as well 94
as pro-oxidant compounds (oxidized glutathione 95
(GSSG) and thiobarbituric acid-reactive substances 96
(TBARS)) were investigated in whole blood cells 97
from MCI and AD patients. In addition, differences 98
by sex were also considered. Moreover, the relation- 99
ship between each of the redox parameters studied 100
and the degree of cognitive performance assessed by 101
the Mini-Mental State Examination (MMSE) were 102
also investigated. 103
MATERIALS AND METHODS 104
Subjects and clinical classification 105
A total of 70 volunteers were selected and divided 106
into three experimental groups: control subjects 107
(n = 30), MCI patients (n = 20) and mild AD (mAD) 108
patients (n = 20). All subjects were recruited by the 109
Neurology Department of the Hospital 12 Octubre of 110
Madrid. The AD diagnosis was established according 111
to the guidelines of the National Institute on Neu- 112
rological Disorders and Stroke and the Alzheimer’s 113
Disease and Related Disorders Association (NINDS- 114
ADRDA) [22]. For MCI subjects he following 115
inclusion criteria applied: 1) memory complaint, cor- 116
roborated by an informant; 2) objective memory 117
impairment detected by neuropsychological evalua- 118
tion; 3) largely intact general cognitive function; 4) 119
essentially preserved activities of daily living; and 120
5) non-demented [23]. Disease severity and normal 121
cognitive function was determined by a clinician’s 122
judgment based on a structured interview with the 123
patient and the results of the Spanish Version of the 124
Clinical Dementia Rating (CDR) and the MMSE tests 125
[24]. The MCI group included both amnestic and non- 126
amnestic patients. In both MCI men and women, the 127
proportion of amnestic subjects was 40%. Given that 128
no statistically significant differences in the mark- 129
ers investigated were found between amnestic and 130
non-amnestic patients, data are shown together. All 131
subjects included in the study had at least, a basic 132
education and they were able to read and write. 133
Inclusion criteria for the age-matched control group 134
were no memory complaints and with 0 score on the 135
CDR randomly chosen from the general population. 136
Demographic details and MMSE test results of the 137
different study groups are summarized in Table 1. 138
All subjects were subjected to a clinical survey and 139
physical examination. Those with diabetes, cardio- 140
vascular disease, cancer or chronic inflammatory 141
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Table 1
Demographic data and cognitive performance of control group,
mild cognitive impairment (MCI) patients and Alzheimer’s disease
(AD) patients. Data of age and MMSE score are reported as the
first and third quartile, respectively. All control individuals had a
CDR score of 0, MCI subjects of 0.5, and AD patients of 1. F,
female; M, male; MMSE, Mini-Mental State Examination; CDR,
Clinical Dementia Rating; n.e., not evaluated
Control MCI AD
N (F/M) 30 (15/15) 20 (10/10) 20 (10/10)
Age (y) 72.00–76.00 74.00–76.75 72.00–76.00
MMSE score n.e. 24.00–26.00 17.00–24.00
CDR score 0 0.5 1
APOE 3/4/ 1/29 7/13 6/14
APOE 3/3
diseases were not included in this study. All proce-142
dures were carried out according to the Declaration143
of Helsinki, and approval was obtained from the144
corresponding Research Ethic Committees. Written145
informed consent was obtained from all participants146
or representatives.147
Extraction of human blood samples148
Blood samples were obtained using sodium cit-149
rate as anticoagulant. Whole blood cells (including150
erythrocytes and total leukocytes) were obtained151
as previously described [25]. Aliquots of periph-152
eral blood were diluted 1:1 in RPMI 1640 (Gibco,153
Canada) and were incubated 4 h at 37◦C in a saturated154
atmosphere of humidity and CO2. After centrifuga-155
tion at 900 g 10 min, plasma was removed and whole156
blood cell pellets were stored at –80ºC until used.157
Superoxide dismutase activity158
SOD activity was measured using a quantitative159
colorimetric assay kit (EnzyChrom™ ESOD-100,160
BioAssay Systems, Hayward, CA).161
Catalase activity162
CAT activity was quantified as previously reported163
by Beers and Sizer [26] with some modifications [25].164
Whole blood cells were resuspended in oxygen-free165
phosphate buffer (pH 7.4 50 mM). Then, they were166
sonicated, centrifuged at 3200 g 20 min and super-167
natants were obtained. H2O2 (14 mM) was used as168
substrate. Supernatants were diluted 1:1000 prior the169
assay. The reaction was calculated by following the170
absorbance decline at 240 nm over 80 s. In the same171
samples, protein concentration was calculated (BCA172
protein assay kit (Sigma-Aldrich) and the results are173
expressed as units (U) of catalase activity/milligram 174
of protein (U CAT/mg protein). 175
Glutathione peroxidase activity 176
GPx activity was analyzed by using a previous 177
method [27] with some modifications [25]. Whole 178
blood pellets were resuspended in oxygen-free phos- 179
phate buffer (pH 7.4 50 mM). Then, they were 180
sonicated and after centrifugation at 3200 g at 4◦C for 181
20 min, supernatants were collected. Human super- 182
natants were diluted 1:30 prior the assay. Cumene 183
hydroperoxide was used as substrate (cumene-OOH; 184
Sigma). The activity was followed measuring the 185
absorbance decline at 340 nm over 5 min. Protein 186
concentration was calculated as described above. 187
The results are expressed as units (U) of glutathione 188
peroxidase activity/milligram of protein (U GPx/mg 189
protein). 190
Glutathione reductase activity 191
GR activity was analyzed following a method 192
previously described [28] with some modifications 193
[25]. Whole blood cells were resuspended in oxygen- 194
free phosphate buffer (pH 7.4 50 mM). Then, they 195
were sonicated, centrifuged at 3200 g at 4◦C 20 min 196
and supernatants were collected. Human supernatants 197
were diluted 1:5 prior the assay. GSSG (80 mM) was 198
used as substrate and, by following the absorbance 199
decline at 340 nm over 5 min, the activity was 200
calculated. Protein concentration was evaluated as 201
described above. The results are expressed as units 202
(U) of Glutathione reductase/per milligram of protein 203
(U GR/mg protein). 204
Glutathione concentration 205
Both reduced GSH and GSSG were measured 206
following a fluorometric assay [29] with some mod- 207
ifications [25]. This method relies on the reaction 208
capacity that glutathione (both GSSG and GSH) 209
shows with o-phthalaldehyde (OPT), at pH 12 and 210
pH 8, respectively, forming a fluorescent compound. 211
Whole blood cells were resuspended in phosphate 212
buffer (pH 8 50 mM EDTA 0.1 M). Then, sam- 213
ples were sonicated, 7.5L of HClO4 (60%) were 214
added and they were centrifuged 10 min at 9500 g. 215
10L from supernatants were dispensed into 96 216
black plates. For GSH quantification, OPT (1 mg/mL) 217
was dispensed into the wells. For the quantification 218
of GSSG, N-ethylmaleimide (NEM, 0.04 M) was 219
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dispensed into each well and after a 30 min incu-220
bation, NaOH (pH 12) and OPT were added. After221
15 min incubation with OPT, fluorescence was mea-222
sured at 420 nm. Protein concentration was calculated223
as described above. Results are expressed as nmol of224
GSSG/mg protein or GSH/mg protein. In addition,225
GSSG/GSH ratio was calculated for each sample.
226
Thiobarbituric acid-reactive substances227
concentration228
Quantification of TBARS was achieved using the229
commercial kit “Lipid peroxidation (MDA) Assay230
Kit” (Biovision, USA). To prevent further peroxida-231
tion of lipids during the preparation of the sample232
or during the heating step, the antioxidant butylated233
hydroxy-toluene (BHT) was added to the lysis buffer234
at a final concentration of 0.1 mM. Briefly, peritoneal235
leukocytes and whole blood cells were resuspended in236
300l MDA lysis buffer (containing BHT), sonicated237
and centrifuged at 13000 g for 10 min. Supernatants238
were collected, mixed with thiobarbituric acid (TBA)239
and incubated in a water bath at 95◦C for 60 min.240
Then, after centrifugation at 13000 g 10 min, super-241
natants were obtained, added into a 96-well plate242
and absorbance at 532 nm was measured. Protein243
concentrations were calculated as described above.244
Because TBA reacts with more aldehydes than mal-245
ondialdehyde, we will refer to the results obtained246
as TBA-reactive substances, even though the con-247
centrations were related to a standard curve using248
malondialdehyde alone, and therefore, the results are249
expressed as nmol MDA/mg protein.250
Statistical analysis251
Statistical analysis of the results was performed252
with SPSS 21.0 (SPSS, Chicago, IL, USA) soft-253
ware. For comparison of variables, the nonparametric254
Kruskal-Wallis test was carried out followed by255
Mann-Whitney U test to determine significant dif-256
ferences between groups. The Pearson correlation257
coefficient was used to test for correlation between258
redox parameters and MMSE scores from MCI and259
AD patients. Two-sided p < 0.05 was considered the260
minimum level of significance.
261
RESULTS262
The main characteristics of the three groups of indi-263
viduals enrolled in this study are reported in Table 1.264
There was the same proportion of men and women 265
in each group. The three groups comprised subjects 266
from the same age interval. Compared to healthy 267
controls, a higher proportion of patients with MCI 268
and AD were apolipoprotein (APOE) 3/4 carri- 269
ers. The results regarding antioxidant parameters are 270
shown in Fig. 1. AD patients showed higher CAT 271
activity (p < 0.001) and lower GPx and GR activities 272
and GSH concentration (p < 0.001) than age-matched 273
controls, and even lower GPx activity and GSH con- 274
centration than MCI patients (p < 0.01). MCI patients 275
also showed higher CAT activity (p < 0.001) and 276
lower GPx and GR activities (p < 0.001) than con- 277
trols. With respect to oxidant parameters (Fig. 2), AD 278
patients showed higher GSSG, GSSG/GSH ratio, and 279
TBARS concentrations (p < 0.05 for GSSG; p < 0.001 280
for GSSG/GSH and TBARS) than age-matched con- 281
trols. MCI patients showed higher GSSG/GSH ratio 282
(p < 0.01) and TBARS concentration (p < 0.001) than 283
controls. Within MCI and AD groups, subjects were 284
further classified depending on the APOE genotype, 285
although no non-statistically significant differences 286
were found in any redox marker due to the presence 287
of APOE 3/3 or 3/4 genotype. 288
Previous data were analyzed including total popu- 289
lation. Then, an additional analysis was performed 290
subdividing groups by sex. With respect to sex- 291
related differences in antioxidant parameters (Fig. 3), 292
control men showed higher SOD and GR activi- 293
ties (p < 0.01; p < 0.05) and lower CAT (p < 0.05) 294
than control women. Within MCI and AD patients 295
no significant differences in antioxidant parameters 296
were found due to sex. Nevertheless, AD women 297
showed higher SOD and CAT activities (p < 0.01; 298
p < 0.05) and lower GPx, GR, and GSH concentration 299
(p < 0.05) than age-matched control women. AD men 300
showed higher CAT activity (p < 0.001) and lower 301
GPx, GR, and GSH (p < 0.001) than age-matched 302
control men and also lower GPx (p < 0.001) and GSH 303
(p < 0.05) than MCI men. With respect to individu- 304
als with MCI, MCI women showed lower GPx and 305
GR activities (p < 0.01; p < 0.05; respectively) than 306
control women, whereas MCI men showed higher 307
CAT (p < 0.001) and lower GPx (p < 0.05) and GR 308
activities (p < 0.01) than control men. With regard to 309
oxidant parameters (Fig. 4), no statistically signifi- 310
cant differences were found within sexes, either in 311
control, MCI, and AD groups. However, both AD 312
men and women displayed higher GSSG/GSH ratios 313
(p < 0.05; p < 0.01; respectively) and higher TBARS 314
(p < 0.01) than their controls. In addition, both MCI 315
men and women showed higher TBARS (p < 0.05; 316
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Fig. 1. Antioxidant parameters in blood cells from mild cognitive impairment (MCI) and Alzheimer’s disease (AD) patients versus age-
matched controls. A) Superoxide dismutase activity; B) Catalase activity; C) Glutathione peroxidase activity; D) Glutathione reductase
activity; E) Reduced glutathione concentration. The central rectangle spans the first to the third quartile (the interquartile range or IQR) and
the horizontal bar depicts the median of data. Error bars depict the highest and lowest point within each data set. ***p < 0.001 with respect
to age-matched controls. ##p < 0.01 with respect to MCI patients.
A
C
B
Fig. 2. Oxidant parameters in blood cells from mild cognitive impairment (MCI) and Alzheimer’s disease (AD) patients versus age-matched
controls. A) Oxidized glutathione (GSSG) concentration; B) GSSG/GSH ratio; C) TBA-reactive substances concentration. The central
rectangle spans the first to the third quartile (the interquartile range or IQR) and the horizontal bar depicts the median of data. Error bars
depict the highest and lowest point within each set of data. *p < 0.05; **p < 0.01; ***p < 0.001 with respect to age-matched controls.
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A B
D E
C
Fig. 3. Antioxidant parameters in blood cells from men (grey boxes) and women (white boxes) with mild cognitive impairment (MCI)
(N = 10, both men and women groups) and Alzheimer’s disease (AD) patients (N = 10, both men and women groups) versus age-matched
controls (N = 15, both men and women groups). A) Superoxide dismutase activity; B) Catalase activity; C) Glutathione peroxidase activity;
D) Glutathione reductase activity; E) Reduced glutathione concentration. The central rectangle spans the first to the third quartile (the
interquartile range or IQR) and the horizontal bar depicts the median of data. Error bars depict the highest and lowest point within each set of
data. *p < 0.05; **p < 0.01; ***p < 0.001 with respect to age and sex-matched controls. #p < 0.05; ###p < 0.001 with respect to sex-matched
MCI patients. +p < 0.05; ++p < 0.01 between sexes within the same group.
A B
C
Fig. 4. Oxidant parameters in blood cells from men (grey boxes) and women (white boxes) with mild cognitive impairment (MCI) (N = 10,
both men and women groups) and Alzheimer’s disease (AD) patients (N = 10, both men and women groups) versus age-matched controls
(N = 15, both men and women groups). A) Oxidized glutathione (GSSG) concentration; B) GSSG/GSH ratio; C) TBA-reactive substances
concentration. The central rectangle spans the first to the third quartile (the interquartile range or IQR) and the horizontal bar depicts the
median of data. Error bars depict the highest and lowest point within each set of data. *p < 0.05; **p < 0.01 with respect to age and sex-matched
controls.
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p < 0.01; respectively) than their sex-matched317
controls.318
In addition, the individual association of each319
redox parameter with cognitive decline was further320
investigated to order to identify which redox marker321
can be used to distinguish between MCI and AD322
patients. For this purpose, the Pearson correlation323
coefficient was calculated for each redox marker324
and the MMSE scores obtained for MCI and AD325
groups together, including men and women. Regard-326
ing antioxidant parameters, a statistically significant327
positive correlation was found between GR activ-328
ity and GSH concentration (R = 0.350, R = 0.371,329
p < 0.05) and MMSE score. With respect to oxidant330
parameters, a statistically significant negative corre-331
lation was found between GSSG concentration and332
GSSG/GSH ratio (R = –0.373, R = –0.332, p < 0.05)333
and MMSE score.334
DISCUSSION335
Research on AD is moving forward at a very rapid336
pace. Clinical investigators are trying to move the337
diagnostic threshold for dementia and AD back to338
earlier stages of progression, while other scientists339
are correspondingly attempting to define biomarkers340
and genetic susceptibilities that will add specificity341
to the clinical diagnoses. As such, research in MCI342
will be likely to push back the threshold of recogni-343
tion to an earlier state in the disease process to allow344
intervention at an earlier point than is currently done345
in typical AD clinical trials [30].346
In AD, oxidative stress is one of the earliest events347
occurring prior to the onset of symptoms and it has348
been recognized as an essential contributor to the349
pathogenesis and progression of the disease [8, 31,350
32]. Products of free radical damage, such as alde-351
hydes or lipid hydroperoxides, may diffuse into the352
blood where they can be detected. Moreover, it has353
been found that blood-brain barrier (BBB) permeabil-354
ity significantly increases in both AD and vascular355
dementia as compared to aging controls [33, 34].356
Increased BBB permeability has been shown to trig-357
ger a chain of events leading to neuronal dysfunction358
and damage, as well as to specific clinical syndromes,359
including dementia [35]. In this context, oxidative360
stress has been shown to contribute to an increase361
in BBB permeability [36]. Consequently, oxidative362
stress parameters represent potential biomarkers in363
blood for diagnosis of AD. In addition, other dis-364
eases accompanied by free radical production, such365
as diabetes or cardiovascular diseases, may influ- 366
ence the presence of free radical products in the 367
blood. This could explain the fact that the results 368
of oxidative stress markers in AD, in several stud- 369
ies, have not been consistent using blood samples 370
[37]. Another limitation towards the establishment 371
of oxidative stress markers for an early AD diagnosis 372
relies on the use of different sample types of study, 373
such as plasma, serum, mononuclear blood leuko- 374
cytes, isolated erythrocytes, or whole blood cells 375
(containing leukocytes and erythrocytes). Thus, most 376
of the studies have been focused on plasma and serum 377
samples [38–46]. However, the redox status of plasma 378
is highly influenced by diet, and most antioxidant 379
enzymatic defense systems and compounds are intra- 380
cellular. In a previous study from our group, it was 381
demonstrated that the redox state of whole blood 382
cells (erythrocytes and leukocytes) reflects that of iso- 383
lated neutrophils, evidenced by higher GSSG/GSH 384
ratio and MDA concentration in severe AD patients 385
compared to mild AD patients and controls [17]. 386
Therefore, in the present study whole blood cells 387
were used given that this sample type is clinically 388
more feasible, reproducible, cost effective, easy to 389
implement and apply, compared to purified and iso- 390
lated neutrophils and mononuclear blood leukocytes 391
[17]. 392
The results from the present study highlight the 393
existence of an altered redox status in whole blood 394
cells from AD patients and interestingly, some of the 395
altered redox parameters are already affected in MCI 396
patients. Given that the regulation of the redox bal- 397
ance in bloodstream is complex and in order to have a 398
wide picture, several antioxidant and oxidant parame- 399
ters were investigated in the present study. The results 400
reveal that AD patients have higher CAT activity, 401
GSSG and TBARS concentrations, and GSSG/GSH 402
ratios, and lower GPx and GR activities, and GSH 403
concentrations, compared to age-matched controls. 404
In addition, MCI patients have a higher CAT activity 405
and TBARS concentration, and lower GPx and GR 406
activities than age-matched controls. 407
Regarding antioxidant enzyme activities, which 408
constitute the first line of defense against generation 409
of free radicals, we found striking differences. The 410
significance of antioxidant changes upon conditions 411
of oxidative stress is strongly under debate, since 412
antioxidants might be induced by oxidative stress 413
(and therefore their activity/levels may increase) or 414
else be consumed (thus decreasing their activity 415
and levels) [47]. Our results demonstrate that SOD 416
activity was similar between MCI and AD patients 417
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and control individuals, which agrees with previ-418
ous reported results [48–50], although higher SOD419
activity was found in AD women compared to age420
and sex-matched controls. Other studies have also421
found higher SOD activity in erythrocytes from AD422
patients by analyzing total population, which con-423
sisted mainly of women [51, 52]. With respect to424
CAT activity, both MCI and AD patients show higher425
catalase activity, which has also been found in other426
studies [52, 53]. This higher enzymatic activity could427
probably be a compensatory mechanism to counter-428
act the increased H2O2 that has been reported in these429
patients. On the contrary, GPx activity was found to430
be lower in MCI and AD patients compared to con-431
trol subjects, as has been previously reported [50].432
Both CAT and GPx catalyze the conversion of H2O2433
into water. The question is why does CAT activity434
increase, and GPx decrease in MCI and AD patients?435
From a kinetic point of view, GPx has a much436
higher affinity for H2O2 than CAT, therefore, H2O2437
is principally degraded by GPx in normal conditions.438
However, when the H2O2 concentration increases,439
as in severe oxidative conditions, the CAT contribu-440
tion for its degradation concomitantly increases [54].441
In addition, CAT mediates conversion of H2O2 into442
water without requiring additional reducing equiva-443
lents and thus, no energy is required from the cell444
[55]. Therefore, this could be the reason why CAT445
activity is enhanced and GPx activity is diminished in446
both MCI and AD patients. Moreover, GPx also cat-447
alyzes the reduction of lipidic peroxides in addition to448
H2O2, thus acting on more sensitive cellular targets.449
McCay et al. [56] showed that GPx protects biological450
membranes by preventing lipid peroxidation prop-451
agation. Thus, the impaired GPx activity found in452
blood cells from MCI and AD patients would exacer-453
bate the accumulation of lipid peroxidation products.454
In fact, in the present study, it was found that MCI and455
AD patients have higher TBARS concentrations in456
whole blood cells compared to age and sex-matched457
controls. Given that lipid peroxidation is a damage458
marker of oxidative stress, it has been proposed as459
one of the most promising markers in AD diagnosis460
[57]. Some authors suggested that lipid peroxidation461
in the brain might be one of the factors responsible462
for cognitive deterioration, and a negative correlation463
between MDA concentration in plasma and severity464
of the AD stage has been reported [37, 53, 57, 58].465
However, we found no association between TBARS466
concentration in blood cells and MMSE scores, which467
could be due to the lack of AD patients in more468
advanced stages of the disease.469
The glutathione cycle is one of the most impor- 470
tant intracellular mechanisms that play a key role in 471
the preservation of an adequate intracellular redox 472
state [59]. In the present study, AD patients showed 473
lower GR activities and GSH concentrations, together 474
with higher GSSG concentrations and GSSG/GSH 475
ratios. Nevertheless, MCI patients only showed lower 476
GR activity compared to age-matched controls. Thus, 477
these results suggest that this activity gets impaired in 478
early stages of the disease whereas in more advanced 479
stages of AD an accumulation of GSSG and an 480
exhaustion of GSH occur. Interestingly, the param- 481
eters involved in the glutathione cycle (GR, GSH, 482
GSSG, GSSG/GSH) were the most directly related 483
to the degree of cognitive impairment, measured by 484
MMSE, in accordance with other studies [60, 61]. 485
With respect to AD prevalence, it is known that its 486
incidence is higher in women than in men and this 487
cannot simply be attributed to the higher longevity of 488
women versus men, because it is also higher in young 489
ages [62]. Thus, there must be a specific pathogenic 490
mechanism to explain the higher incidence of AD 491
cases in women. The results from the present study 492
demonstrate that in the absence of pathology there 493
are statistically significant differences in antioxidant 494
activities due to sex, whereas in MCI and AD individ- 495
uals, these differences were no longer noticeable. It 496
has been suggested that sex-related differences could 497
be related to the role of sexual hormones. Estro- 498
gens are known to upregulate the expression of SOD 499
and GPx [62]. However, post-menopausal women 500
experience a sharp fall in estrogens whereas men gen- 501
erally experience a more gradual age-related decline 502
in testosterone [63]. This difference between how 503
rapidly and significantly the female versus male pri- 504
mary sex hormones decline could explain in part why 505
women are more vulnerable to oxidative stress in the 506
elderly and why the incidence of AD is higher in 507
women than in men. 508
Despite not having found sex-related differences 509
between MCI and AD individuals, it was observed 510
that whereas the alterations in antioxidant defense 511
mechanisms were more significant in AD men than in 512
AD women in comparison to their respective controls 513
(such as higher CAT and lower GPx and GR activities 514
and GSH concentration), the increase in oxidant com- 515
pounds was more significant in AD women than in 516
AD men (in GSSG/GSH ratios and TBARS concen- 517
trations) compared to their respective controls. Thus, 518
these results suggest that the increased oxidative dam- 519
aged products found in women, are not the result of 520
an impaired antioxidant defense system but rather the 521
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consequence of the overproduction of reactive oxy-522
gen species, as has been previously suggested [64].523
According to this, it has been reported that mitochon-524
dria from old female mice produce more reactive525
oxygen species in the presence of A peptide than526
those from old male mice [62].527
In addition to age and sex, the presence of the528
4 allele in APOE gene has been recognized as a529
major risk for sporadic AD [65–67]. However, its530
relationship with oxidative stress is controversial.531
A few studies have found a relationship between532
the 4 allele APOE genotype and peripheral mark-533
ers of oxidative damage, such as higher hydroxyl534
radical levels [68] and MDA [40] in plasma than535
those without this allele. However, others have found536
no differences [69], similar to that observed in the537
present study. The lack of statistically significant dif-538
ferences in our study could be due to the small number539
of patients with the 4 allele in APOE.540
In conclusion, the major strength of our study541
is that we performed analysis in blood cells from542
patients with MCI and AD. With this kind of sam-543
ple, we have demonstrated that some redox markers544
were affected in AD patients (lower GPx and GR545
activities and GSH concentrations and higher CAT546
activity and TBARS concentrations) with respect to547
control age-matched individuals. Interestingly, some548
of these markers were already altered in MCI patients549
from both sexes (such as GPx and GR activities and550
TBARS concentration) and therefore, could be used551
for early diagnosis of AD. In addition, other redox552
markers such as GR activity, GSH and GSSG con-553
centrations, and GSSG/GSH ratios were found to be554
associated with cognitive decline. Even though these555
associations were modest due to the small sample556
size included in the present study, our data highlight557
the importance and the impact of peripheral redox558
state and homeostatic systems during the early cog-559
nitive decline leading to dementia. However, because560
oxidative stress and damage occur in several dis-561
eases (including other types of dementia), another562
group of demented subjects, distinct from AD, should563
be included in future studies. Still, given the easy564
obtainability of the sample type used and the sim-565
plicity of the assays performed, the combination of566
some redox whole blood cell markers, such as GPx567
and GR activities and TBARS concentration could568
be used to define their MCI stage. However, oth-569
ers like GR activity, GSH and GSSG concentrations,570
and GSSG/GSH ratios have potential to be used in571
monitoring the progression of AD, once the pathol-572
ogy is established, in the clinical setting. Thus, we573
believe that the integration of several of the investi- 574
gated parameters into a mathematical model could be 575
used as a more reliable and consistent tool in the clini- 576
cal setting. Nevertheless, a longitudinal design should 577
be performed in order to elucidate the relationship 578
between these markers and the course of the disease. 579
Thus, although preliminary, these results could pro- 580
vide a benchmark for future work aimed at finding 581
prognostic markers of AD. 582
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